» Articles » PMID: 38164157

Theranostic Platform Combining Highly Localized Magnetic Fluid Hyperthermia, Magnetic Particle Imaging, and Thermometry in 3D

Abstract

Theranostic platforms, combining diagnostic and therapeutic approaches within one system, have garnered interest in augmenting invasive surgical, chemical, and ionizing interventions. Magnetic particle imaging (MPI) offers a quite recent alternative to established radiation-based diagnostic modalities with its versatile tracer material (superparamagnetic iron oxide nanoparticles, SPION). It also offers a bimodal theranostic framework that can combine tomographic imaging with therapeutic techniques using the very same SPION. : We show the interleaved combination of MPI-based imaging, therapy (highly localized magnetic fluid hyperthermia (MFH)) and therapy safety control (MPI-based thermometry) within one theranostic platform in all three spatial dimensions using a commercial MPI system and a custom-made heating insert. The heating characteristics as well as theranostic applications of the platform were demonstrated by various phantom experiments using commercial SPION. : We have shown the feasibility of an MPI-MFH-based theranostic platform by demonstrating high spatial control of the therapeutic target, adequate MPI-based thermometry, and successful interleaved MPI-MFH application. : MPI-MFH-based theranostic platforms serve as valuable tools that enable the synergistic integration of diagnostic and therapeutic approaches. The transition into studies will be essential to further validate their potential, and it holds promising prospects for future advancements.

Citing Articles

Ranking Magnetic Colloid Performance for Magnetic Particle Imaging and Magnetic Particle Hyperthermia.

Carlton H, Salimi M, Arepally N, Bentolila G, Sharma A, Bibic A Adv Funct Mater. 2025; 35(2):2412321.

PMID: 39882193 PMC: 11774450. DOI: 10.1002/adfm.202412321.


Magnetic Particle Imaging-Guided Thermal Simulations for Magnetic Particle Hyperthermia.

Carlton H, Arepally N, Healy S, Sharma A, Ptashnik S, Schickel M Nanomaterials (Basel). 2024; 14(12).

PMID: 38921935 PMC: 11206764. DOI: 10.3390/nano14121059.


In Vitro Study of Tumor-Homing Peptide-Modified Magnetic Nanoparticles for Magnetic Hyperthermia.

Zhou S, Tsutsumiuchi K, Imai R, Miki Y, Kondo A, Nakagawa H Molecules. 2024; 29(11).

PMID: 38893510 PMC: 11174109. DOI: 10.3390/molecules29112632.


Recent Developments in Magnetic Hyperthermia Therapy (MHT) and Magnetic Particle Imaging (MPI) in the Brain Tumor Field: A Scoping Review and Meta-Analysis.

Rentzeperis F, Rivera D, Zhang J, Brown C, Young T, Rodriguez B Micromachines (Basel). 2024; 15(5).

PMID: 38793132 PMC: 11123314. DOI: 10.3390/mi15050559.


Key Contributors to Signal Generation in Frequency Mixing Magnetic Detection (FMMD): An In Silico Study.

Engelmann U, Simsek B, Shalaby A, Krause H Sensors (Basel). 2024; 24(6).

PMID: 38544208 PMC: 10975814. DOI: 10.3390/s24061945.


References
1.
Remmo A, Wiekhorst F, Kosch O, Lyer S, Unterweger H, Kratz H . Determining the resolution of a tracer for magnetic particle imaging by means of magnetic particle spectroscopy. RSC Adv. 2023; 13(23):15730-15736. PMC: 10208046. DOI: 10.1039/d3ra01394d. View

2.
Roohi F, Lohrke J, Ide A, Schutz G, Dassler K . Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2012; 7:4447-58. PMC: 3420593. DOI: 10.2147/IJN.S33120. View

3.
Yang X, Shao G, Zhang Y, Wang W, Qi Y, Han S . Applications of Magnetic Particle Imaging in Biomedicine: Advancements and Prospects. Front Physiol. 2022; 13:898426. PMC: 9285659. DOI: 10.3389/fphys.2022.898426. View

4.
Mason E, Cooley C, Cauley S, Griswold M, Conolly S, Wald L . Design analysis of an MPI human functional brain scanner. Int J Magn Part Imaging. 2017; 3(1). PMC: 5526464. DOI: 10.18416/ijmpi.2017.1703008. View

5.
Bodei L, Herrmann K, Schoder H, Scott A, Lewis J . Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022; 19(8):534-550. PMC: 10585450. DOI: 10.1038/s41571-022-00652-y. View